Home/Filings/4/0001213900-20-043289
4//SEC Filing

KRAUSS MARLENE 4

Accession 0001213900-20-043289

CIK 0001690080other

Filed

Dec 16, 7:00 PM ET

Accepted

Dec 17, 5:29 PM ET

Size

15.6 KB

Accession

0001213900-20-043289

Insider Transaction Report

Form 4
Period: 2020-12-14
KRAUSS MARLENE
DirectorChief Executive Officer10% Owner
Transactions
  • Sale

    Common Stock

    2020-12-15$2.40/sh17,877$42,9052,543,676 total(indirect: See footnote)
  • Sale

    Common Stock

    2020-12-17$2.49/sh12,103$30,1362,006,858 total(indirect: See footnote)
  • Other

    Common Stock

    2020-12-16+334,608334,608 total
  • Sale

    Common Stock

    2020-12-17$2.44/sh4,403$10,7432,018,961 total(indirect: See footnote)
  • Other

    Common Stock

    2020-12-16520,3122,023,364 total(indirect: See footnote)
  • Sale

    Common Stock

    2020-12-14$2.45/sh10,000$24,5002,561,553 total(indirect: See footnote)
Transactions
  • Sale

    Common Stock

    2020-12-17$2.49/sh12,103$30,1362,006,858 total(indirect: See footnote)
  • Sale

    Common Stock

    2020-12-17$2.44/sh4,403$10,7432,018,961 total(indirect: See footnote)
  • Other

    Common Stock

    2020-12-16+334,608334,608 total
  • Other

    Common Stock

    2020-12-16520,3122,023,364 total(indirect: See footnote)
  • Sale

    Common Stock

    2020-12-15$2.40/sh17,877$42,9052,543,676 total(indirect: See footnote)
  • Sale

    Common Stock

    2020-12-14$2.45/sh10,000$24,5002,561,553 total(indirect: See footnote)
Footnotes (3)
  • [F1]The securities are held directly by KBL IV Sponsor LLC ("KBL Sponsor"). Dr. Marlene Krauss, the former Chief Executive Officer, and a former member of the Board of Directors, of the issuer, is the sole managing member of KBL Sponsor. Consequently, she may be deemed the beneficial owner of the securities of the issuer held by KBL Sponsor, and she has sole voting and dispositive control over such securities. Dr. Krauss disclaims beneficial ownership over any securities of the issuer owned by KBL Sponsor in which she does not have a pecuniary interest.
  • [F2]KBL Sponsor made a pro rata distribution for no consideration of an aggregate of 520,312 shares of the common stock of the issuer to its members on December 16, 2020.
  • [F3]Represents 334,608 shares of the issuer's common stock that were received by Dr. Krauss in a pro rata distribution made by KBL Sponsor to its members on December 16, 2020. In prior reports, Dr. Krauss reported indirect beneficial ownership of all of the shares of the issuer's common stock held by KBL Sponsor.

Documents

1 file

Issuer

180 Life Sciences Corp.

CIK 0001690080

Entity typeother

Related Parties

1
  • filerCIK 0001033308

Filing Metadata

Form type
4
Filed
Dec 16, 7:00 PM ET
Accepted
Dec 17, 5:29 PM ET
Size
15.6 KB